Exosomes carrying immunoinhibitory proteins and their role in cancer

Clinical and Experimental Immunology

Volumn 189, Issue 3, 2017, Pages 259-267

  Whiteside, T L ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

cancer; exosomes; immune suppression; information transfer; tumour derived exosomes

Indexed keywords

IMMUNOINHIBITORY PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

CANCER INHIBITION; CELL SELECTION; EFFECTOR CELL; EXOSOME; HUMAN; IMMUNOCOMPETENT CELL; LYMPHOCYTE SUBPOPULATION; MALIGNANT NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL; TUMOUR DERIVED EXOSOME; IMMUNOLOGY; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; ULTRASTRUCTURE;

EXOSOMES; HUMANS; NEOPLASMS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85020379702     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12974     Document Type: Review

References (70)

1. Boyiadzis M, Whiteside TL. Information transfer by exosomes: a new frontier in hematologic malignancies. Blood Rev 2015; 29:281–90.
2. Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 1983; 97:329–39.
3. Pan BT, Johnstone RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983; 33:967–78.
4. Antonyak MA, Cerione RA. Microvesicles as mediators of intercellular communication in cancer. Methods Mol Biol 2014; 1165:147–73.
5. Abels ER, Breakefield XO. Introduction to extracellular vesicles: biogenesis, RNA cargo selection, content, release, and uptake. Cell Mol Neurobiol 2016; 36:301–12.
6. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 2013; 200:373–83.
7. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol 2009; 19:43–51.
8. Cocucci E, Meldolesi J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. Trends Cell Biol 2015; 25:364–72.
9. Chevillet JR, Kang Q, Ruf IK et al. Quantitative and stoichiometric analysis of the microRNA content of exosomes. Proc Natl Acad Sci USA 2014; 111:14888–93.
10. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9:654–9.
11. Kahlert C, Melo SA, Protopopov A et al. Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer. J Biol Chem 2014; 289:3869–75.
12. Colombo M, Moita C, van Niel G et al. Analysis of ESCRT functions in exosome biogenesis, composition and secretion highlights the heterogeneity of extracellular vesicles. J Cell Sci 2013; 126:5553–65.
13. Basu J, Ludlow JW. Exosomes for repair, regeneration and rejuvenation. Exp Opin Biol Ther 2016; 16:489–506.
14. Kumar B, Garcia M, Murakami JL, Chen CC. Exosome-mediated microenvironment dysregulation in leukemia. Biochim Biophys Acta 2016; 1863:464–70.
15. Aharon A, Brenner B. Microparticles, thrombosis and cancer. Best Pract Res Clin Haematol 2009; 22:61–9.
16. Lo Cicero A, Stahl PD, Raposo G. Extracellular vesicles shuffling intercellular messages: for good or for bad. Curr Opin Cell Biol 2015; 35:69–77.
17. Toth B, Lok CA, Boing A et al. Microparticles and exosomes: impact on normal and complicated pregnancy. Am J Reprod Immunol 2007; 58:389–402.
18. Zhang HG, Grizzle WE. Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol 2014; 184:28–41.
19. Teow SY, Nordin AC, Ali SA, Khoo AS. Exosomes in human immunodeficiency virus type I pathogenesis: threat or opportunity? Adv Virol 2016; 2016:9852494.
20. Tan L, Wu H, Liu Y, Zhao M, Li D, Lu Q. Recent advances of exosomes in immune modulation and autoimmune diseases. Autoimmunity 2016; 49:357–65.
21. Vella LJ, Hill AF, Cheng L. Focus on extracellular vesicles: exosomes and their role in protein trafficking and biomarker potential in Alzheimer's and Parkinson's disease. Int J Mol Sci 2016; 17:173.
22. Lee H, Zhang D, Zhu Z, Dela Cruz CS, Jin Y. Epithelial cell-derived microvesicles activate macrophages and promote inflammation via microvesicle-containing microRNAs. Sci Rep 2016; 6:35250.
23. Whiteside TL. Exosomes and tumor-mediated immune suppression. J Clin Invest 2016; 126:1216–23.
24. Atay S, Godwin AK. Tumor-derived exosomes: a message delivery system for tumor progression. Commun Integr Biol 2014; 7:e28231.
25. Whiteside TL. Tumor-derived exosomes and their role in cancer progression. Adv Clin Chem 2016; 74:103–41.
26. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 2005; 11:1010–20.
27. Melo SA, Luecke LB, Kahlert C et al. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature 2015; 523:177–82.
28. Hong CS, Funk S, Muller L, Boyiadzis M, Whiteside TL. Isolation of biologically active and morphologically intact exosomes from plasma of patients with cancer. J Extracell Vesicles 2016; 5:29289.
29. Ludwig S, Floros T, Hong CS, Jackson EK, Lang S, Whiteside TL. Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer. Clin Cancer Res 2017; Epub ahead of print.
30. Keerthikumar S, Chisanga D, Ariyaratne D et al. ExoCarta: a web-based compendium of exosomal cargo. J Mol Biol 2016; 428:688–92.
31. Gross JC, Chaudhary V, Bartscherer K, Boutros M. Active Wnt proteins are secreted on exosomes. Nat Cell Biol 2012; 14:1036–45.
32. Kalra H, Drummen GP, Mathivanan S. Focus on extracellular vesicles: introducing the next small big thing. Int J Mol Sci 2016; 17:170.
33. Rak J, Guha A. Extracellular vesicles – vehicles that spread cancer genes. Bioessays 2012; 34:489–97.
34. Silva M, Melo SA. Non-coding RNAs in exosomes: new players in cancer biology. Curr Genomics 2015; 16:295–303.
35. + T lymphocytes. J Immunol 2009; 183:3720–30.
36. Withrow J, Murphy C, Liu Y, Hunter M, Fulzele S, Hamrick MW. Extracellular vesicles in the pathogenesis of rheumatoid arthritis and osteoarthritis. Arthritis Res Ther 2016; 18:286.
37. King HW, Michael MZ, Gleadle JM. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer 2012; 12:421.
38. Xiao D, Barry S, Kmetz D et al. Melanoma cell-derived exosomes promote epithelial-mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment. Cancer Lett 2016; 376:318–27.
39. Wen SW, Sceneay J, Lima LG et al. The biodistribution and immune suppressive effects of breast cancer-derived exosomes. Cancer Res 2016; 76:6816–27.
40. Mulcahy LA, Pink RC, Carter DR. Routes and mechanisms of extracellular vesicle uptake. J Extracell Vesicles 2014; doi: 10.3402/jev.v3.24641.
41. Muller L, Simms P, Hong CS et al. Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms. OncoImmunology 2017; in press.
42. Whiteside TL. Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 2013; 41:245–51.
43. Taylor DD, Gercel-Taylor C, Lyons KS, Stanson J, Whiteside TL. T-cell apoptosis and suppression of T-cell receptor/CD3-zeta by Fas ligand-containing membrane vesicles shed from ovarian tumors. Clin Cancer Res 2003; 9:5113–9.
44. Clayton A, Mitchell JP, Court J, Mason MD, Tabi Z. Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res 2007; 67:7458–66.
45. Muller L, Mitsuhashi M, Simms P, Gooding WE, Whiteside TL. Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets. Sci Rep 2016; 6:20254.
46. Czystowska M, Han J, Szczepanski MJ et al. IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ 2009; 16:708–18.
47. Szczepanski MJ, Szajnik M, Welsh A, Whiteside TL, Boyiadzis M. Blast-derived microvesicles in sera from patients with acute myeloid leukemia suppress natural killer cell function via membrane-associated transforming growth factor-beta1. Haematologica 2011; 96:1302–9.
48. Syn N, Wang L, Sethi G, Thiery JP, Goh BC. Exosome-mediated metastasis: from epithelial–mesenchymal transition to escape from immunosurveillance. Trends Pharmacol Sci 2016; 37:606–17.
49. Figueiro F, Muller L, Funk S, Jackson EK, Battastini AM, Whiteside TL. Phenotypic and functional characteristics of CD39high human regulatory B cells (Breg). Oncoimmunology 2016; 5:e1082703.
50. Xiang X, Poliakov A, Liu C et al. Induction of myeloid-derived suppressor cells by tumor exosomes. Int J Cancer 2009; 124:2621–33.
51. Bretz NP, Ridinger J, Rupp AK et al. Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J Biol Chem 2013; 288:36691–702.
52. +HLA-DRlo/neg monocytes are elevated in pancreatic cancer and ‘primed’ by tumor-derived exosomes. Oncoimmunology 2017; 6:e1252013.
53. Liu Y, Gu Y, Han Y et al. Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell 2016; 30:243–56.
54. Carissimi C, Carucci N, Colombo T et al. miR-21 is a negative modulator of T-cell activation. Biochimie 2014; 107 Pt B:319–26.
55. +) cells. Clin Exp Immunol 2014; 177:531–43.
56. Szajnik M, Czystowska M, Szczepanski MJ, Mandapathil M, Whiteside TL. Tumor-derived microvesicles induce, expand and up-regulate biological activities of human regulatory T cells (Treg). PLOS ONE 2010; 5:e11469.
57. Peinado H, Aleckovic M, Lavotshkin S et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. Nat Med 2012; 18:883–91.
58. Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res 2007; 67:2912–5.
59. Boniface JD, Poschke I, Mao Y, Kiessling R. Tumor-dependent down-regulation of the zeta-chain in T-cells is detectable in early breast cancer and correlates with immune cell function. Int J Cancer 2012; 131:129–39.
60. Whiteside TL. Down-regulation of zeta-chain expression in T cells: a biomarker of prognosis in cancer? Cancer Immunol Immunother 2004; 53:865–78.
61. Liu Y, Xiang X, Zhuang X et al. Contribution of MyD88 to the tumor exosome-mediated induction of myeloid derived suppressor cells. Am J Pathol 2010; 176:2490–9.
62. Spain L, Larkin J. Combination immune checkpoint blockade with ipilimumab and nivolumab in the management of advanced melanoma. Exp Opin Biol Ther 2016; 16:389–96.
63. Whiteside TL, Demaria S, Rodriguez-Ruiz ME, Zarour HM, Melero I. Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res 2016; 22:1845–55.
64. Whiteside TL. Immune responses to cancer: are they potential biomarkers of prognosis? Front Oncol 2013; 3:107.
65. Galon J, Fox BA, Bifulco CB et al. Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015. J Transl Med 2016; 14:273.
66. Whiteside TL. The potential of tumor-derived exosomes for noninvasive cancer monitoring. Expert Rev Mol Diagn 2015; 18–1.
67. Hong CS, Muller L, Whiteside TL, Boyiadzis M. Plasma exosomes as markers of therapeutic response in patients with acute myeloid leukemia. Front Immunol 2014; 5:160.
68. Battke C, Ruiss R, Welsch U et al. Tumour exosomes inhibit binding of tumour-reactive antibodies to tumour cells and reduce ADCC. Cancer Immunol Immunother 2011; 60:639–48.
69. Boyiadzis M, Hong CS, Whiteside TL. Circulating exosomes carrying an immunosuppressive cargo interfere with adoptive cell therapy in acute myeloid leukemia. Blood 2016; 128:1609.
70. + blast-derived exosomes in acute myeloid leukemia. PLOS ONE 2014; 9:e103310.